Hanping Wang - Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 90 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Characterizations of Multi-Kingdom Gut Microbiota in Immune Checkpoint Inhibitor-Treated Hepatocellular Carcinoma

Chengpei Zhu,Chenchen Zhang, Shanshan Wang,Ziyu Xun,Dongya Zhang,Zhou Lan,Longhao Zhang,Jiashuo Chao,Yajun Liang, Zilun Pu,Cong Ning,Xinting Sang,Xiaobo Yang,Hanping Wang,Xianzhi Jiang,Haitao Zhao

JOURNAL FOR IMMUNOTHERAPY OF CANCERno. 6 (2024)

引用0浏览0WOS引用

Immunosuppression and Phenotypic Plasticity in an Atlas of Human Hepatocholangiocarcinoma

Yiran Li,Ziyu Xun,Junyu Long,Huishan Sun, Xu Yang,Yanyu Wang,Yunchao Wang,Jingnan Xue, Nan Zhang,Junwei Zhang,Jin Bian,Jie Shi,Xiaobo Yang,Hanping Wang,Haitao Zhao

HEPATOBILIARY SURGERY AND NUTRITION（2024）

引用0浏览0WOS引用

Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma

Xinyu Bi,Yinying Lu,Bo Chen, Zhengqiang Yang,Zhixian Hong,Hanping Wang, Yongkun Sun,Xiaodong Wang,Chunwang Yuan, Daobing Zeng,Zhen Huang,Aiping Zhou,Wen Zhang,Shunda Du,Jianjun Zhao,Jianguo Zhou, Yirui Zhai,Xu Che,Hong Zhao,Haitao Zhao,Jianqiang Cai

Liver Cancerpp.1-25, (2024)

引用0浏览0引用

Lenvatinib (lenv) Plus Tislelizumab (tis) Combined with or Without Transarterial Chemoembolization (TACE) in First-Line Treatment of Unresectable Hepatocellular Carcinoma (uhcc): A Prospective, Non-Randomized, Open-Label, Phase II Cohort Study

Nan Zhang, Jiongyuan Li, Mingjian Piao, Chengjie Li,Ziyu Xun, Longhao Zhang,Yanyu Wang, Kai Liu,Shanshan Wang,Hanping Wang,Hai-Tao Zhao

Journal of Clinical Oncologyno. 16_suppl (2024): e16169-e16169

引用0浏览0引用

Management and Treatment of Severe Immune-Related Hepatotoxicity Based on Clinical and Pathological Characteristics

Nan Zhang, Zhaohui Li, Yutao Liu, Xiaohua Shi, Di Shi,Yue Li,Xiaoyan Si,Ziyu Xun, Jing Shao,Haitao Zhao,Hanping Wang

Hepatology International（2024）

引用0浏览0WOS引用

Hepatitis Associated with Immune Checkpoint Inhibitors-Based Combinations of Other Therapies: A Real-World Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System (FAERS) Database

Zhaohui Li, Zixiang Zhou, Nan Zhang, Binhe Tian, Xiangqi Chen, Haitao Zhao,Hanping Wang

Cancer immunology, immunotherapy CIIno. 1 (2024): 25-25

引用0浏览0WOS引用

Liquid Biopsy-Based Prediction of Clinical Benefit from Immune Checkpoint Inhibitors in Advanced Biliary Tract Cancer

Nan Zhang, Yunchao Wang,Mingming Yuan, Jing Shao,Rongrong Chen, Mingjian Piao, Jiongyuan Li, Chengjie Li,Longhao Zhang,Jingnan Xue,Yanyu Wang,Ziyu Xun, Shanshan Wang,Yiran Li, Huishan Sun,Hanping Wang,Hai-Tao Zhao

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Biomarkers and Prognostic Factors of PD-1/PD-L1 Inhibitor-Based Therapy in Patients with Advanced Hepatocellular Carcinoma

Nan Zhang,Xu Yang,Mingjian Piao,Ziyu Xun,Yunchao Wang,Cong Ning,Xinmu Zhang,Longhao Zhang,Yanyu Wang, Shanshan Wang,Jiashuo Chao,Zhenhui Lu,Xiaobo Yang,Hanping Wang,Haitao Zhao

Biomarker Researchno. 1 (2024)

引用0浏览0WOS引用

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer

Kang Miao,Xiaotong Zhang,Hanping Wang,Xiaoyan Si,Li Zhang

Thoracic cancerno. 13 (2023): 1162-1170

引用12浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn